The global diabetes market is projected to double from $32bn to $64bn over the next 15 years as a result of changing demographics and new therapies entering the clinic. Now at epidemic levels, diabetes will affect eight percent of the world’s adult population by 2030. The industry is desperate to develop and embrace new innovations to develop a new pipeline in treating diabetes. Currently almost all treatment relies on insulin which has long been a treatment for diabetes, but they only help with the symptoms rather than cure the disease.
This conference will help delegates in developing safe and effective anti-diabetic pharmaceuticals - bringing together the key industry and academic experts in analysing cutting edge strategies on how to advance the latest anti-diabetic drugs. From pre-clinical testing through to clinical efficacy, this event will give the opportunity to discuss the key issues, while focusing on how to translate current and future innovations (from new molecular targets to regenerative medicines) into their pipeline for successful market access.
+357 22 849 308